Enabling A Smarter Way for Cell SEPARATION in Personalized CAR-T

SmartSep™ enables a large-scale, fully-automated cell separation and beads depletion solution for seamless integration into today’s complex CAR-T production process.

The CAR-T Personalized Medicine
Revolution

In the last few years, chimeric antigen receptor (CAR) T cell therapy has revolutionized the personalized medicine market in the treatment of many types of B-cell-related cancers. This type of cellular therapy redirects a patient’s T cells to recognize and attack their tumor cells. With the recent approval by the FDA of Kymriah™ and Yescarta™ for the treatment of hematologic malignancies, the CAR-T market is seeing extraordinary increased interest. Valued at $291 million in 2018, the CAR-T market is anticipated to grow by over 32% per year until 20251!
diagram car t process

SmartSep™ SEAMLESSLY INTEGRATES WITHIN THE CAR-T PRODUCTION PROCESS

Today, there is a real industry challenge to produce these personalized cell therapy treatments. Alongside the need for personalized production for each patient, manufacturing processes of engineered T cells are highly complex, making them mini-scale in production, labor intensive and time-limited from sample collection to treatment.

SmartSep™ enables a large-scale, fully-automated cell separation solution for seamless integration within today’s complex CAR-T production process. With over 66% of cell manufacturers selecting magnetic-based cell isolation technologies2, our advanced technology overcomes many cited industry challenges3, including bead removal and loss of final cellular product, to be the leading market solution for cell isolation.

SmartSep™ ADVANTAGES FOR CAR-T

Exceptional
isolation
of specific cells
in high yields
and viability

Magnetic
bead depletion
before infusion
back to the
patient

Large-scale,
automated
cell isolation
process